Denali Therapeutics/ US24823R1059 /
| 2024-05-06 9:59:56 PM | Chg. +0.03 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 17.15USD | +0.18% | 14,752 Turnover: 252,259.87 |
-Bid Size: - | -Ask Size: - | 17.71 | 16.93 |
GlobeNewswire
05-01
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343...
GlobeNewswire
04-01
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Med...
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-07
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzym...
GlobeNewswire
02-01
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossin...
GlobeNewswire
01-08
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its ...
GlobeNewswire
2023-11-27
Meet the Companies Named to Computerworld’s 2024 Best Places to Work in IT List
GlobeNewswire
2023-11-07
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
GlobeNewswire
2023-11-07
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spher...
GlobeNewswire
2023-08-30
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (H...
GlobeNewswire
2022-03-15
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krog...
GlobeNewswire
2022-03-09
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Fronto...
GlobeNewswire
2022-02-28
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlig...
GlobeNewswire
2022-02-10
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Synd...
GlobeNewswire
2022-02-01
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...
GlobeNewswire
2022-01-23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...
GlobeNewswire
2022-01-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeu...
GlobeNewswire
2022-01-13
Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
GlobeNewswire
2022-01-10
Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodege...
GlobeNewswire
2021-11-17
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commerc...
GlobeNewswire
2021-11-04
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
